Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 18,156
- Companies
- 1,062
- Drugs tracked
- 3,385
Quick answer
NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Arexvy powder and suspension for suspension for injection Respiratory Syncytial Virus (RSV) vaccine (recombinant, adjuvanted)
GlaxoSmithKline Biologicals S.A.
Respiratory Syncytial Virus Infections
1 trial -
Atenativ 1000 I.E. - Pulver und Lösungsmittel zur Herstellung einer Injektions- oder Infusionslösung, Atenativ, 50 IU/ml, práek a rozpoutědlo pro infuzní roztok, Atenativ 500 I.E. - Pulver und Lösungsmittel zur Herstellung einer Injektions- oder Infusionslösung, Atenativ 50 i.e./ml praek in vehikel za raztopino za infundiranje, Atenativ 50 IU/ml prášek a rozpouštědlo pro infuzní roztok, ATENATIV 50 UI/mL, poudre et solvant pour solution pour perfusion, ATENATIV 50 UI/mL, poudre et solvant pour solution p
Pharma Mar S.A.
Acquired Antithrombin Deficiency (Heparin Resistance)
1 trial -
Atumelnant 120 mg tablets, Atumelnant 80 mg tablets, Tablet
Pharma Mar S.A.
Classic Congenital Adrenal Hyperplasia
1 trial -
Atumelnant 80 mg tablets, Atumelnant 40 mg tablet, Atumelnant 20 mg tablets, Tablet
Pharma Mar S.A.
Classic congenital adrenal hyperplasia
1 trial -
Azacitidin Zentiva 25 mg/ml Pulver zur Herstellung einer Injektionssuspension, Azacitidine 25 mg/mL powder for suspension for injection, SY-1425, Placebo for Tamibarotene (SY-1425), AZACITIDINE
Pharma Mar S.A.
Newly Diagnosed RARA-positive Adult Patients with Higher-risk Myelodysplastic Syndrome
1 trial -
BEFIZAL L.P. 400 mg, comprimé enrobé à libération prolongée, BEZAFIBRATE LP 400 mg, BEFIZAL 200 mg, comprimé pelliculé, Placebo BEZAFIBRATE 200 mg
Pari Pharma GmbH
Subjects with PBC with a non-optimal response to UDCA.
1 trial -
BRUKINSA 80 mg hard capsules, Calquence 100 mg film-coated tablets, IMBRUVICA 140 mg film-coated tablets, Lisaftoclax, IMBRUVICA 140 mg hard capsules, Lisaftoclax, Calquence 100 mg film-coated tablets, IMBRUVICA 140 mg film-coated tablets, Lisaftoclax, Calquence 100 mg hard capsules, IMBRUVICA 140 mg hard capsules, Calquence 100 mg hard capsules
Pharma Mar S.A.
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
1 trial -
Beltavac Polymerized placebo. It is a saline solution without the allergenic extract, BELTAVAC with polymerized extract From Dermatophagoides
Pharma Mar S.A.
Allergic rhinoconjunctivitis due to exposure of house dust mites
1 trial -
Benlysta 200 mg solution for injection in pre-filled pen.
GlaxoSmithKline Biologicals S.A.
connective tissue diseases
1 trial -
Benlysta 200 mg solution for injection in pre-filled syringe., Placebo for Belimumab Solution for Injection, 200 mg/mL. The placebo for Belimumab Solution for Injection, 200 mg/mL is provided as a sterile solution for subcutaneous (SC) injection in single-use prefilled syringes.
GlaxoSmithKline Biologicals S.A.
Lung Diseases, Interstitial
1 trial -
Berotralstat, Orladeyo 150 mg hard capsules, Berotralstat, Berotralstat, Berotralstat
Pharma Mar S.A.
Hereditary Angioedema (HAE)
1 trial -
Betahistine dihydrochloride, BETASERC 24 mg, comprimé
Pharma Mar S.A.
Menière's disease
1 trial -
Bexicaserin, LP352 (bexicaserin) Placebo Oral Solution
Pharma Mar S.A.
Dravet Syndrome
1 trial -
Bexsero suspension for injection in pre-filled syringe Meningococcal group B Vaccine (rDNA, component, adsorbed), Bexsero suspension for injection in pre-filled syringe Meningococcal group B Vaccine (rDNA, component, adsorbed), Bexsero suspension for injection in pre-filled syringe Meningococcal group B Vaccine (rDNA, component, adsorbed), Bexsero suspension for injection in pre-filled syringe Meningococcal group B Vaccine (rDNA, component, adsorbed)
GlaxoSmithKline Biologicals S.A.
Invasive meningococcal disease (IMD)
1 trial -
Bimzelx 160 mg solution for injection in pre-filled syringe, Bimzelx 160 mg solution for injection in pre-filled syringe, Bimzelx 320 mg solution for injection in pre-filled pen, Bimzelx 320 mg solution for injection in pre-filled pen, Placebo matching test. 0.9% sodium chloride solution for injection (unauthorized)., Bimzelx 160 mg solution for injection in pre-filled syringe, Bimzelx 160 mg solution for injection in pre-filled syringe
Pharma Mar S.A.
Palmoplantar Pustulosis
1 trial -
Biosteron, 10 mg, tabletki, Senaxa PR, 2 mg, tabletki o przedłużonym uwalnianiu
Pharma Mar S.A.
Menopause, sleep disorders in the postmenopausal period
1 trial -
Bosulif 500 mg film-coated tablets, Olverembatinib, Bosulif 100 mg film-coated tablets
Pharma Mar S.A.
Chronic Phase Chronic Myeloid Leukemia
1 trial -
CAPECITABINE, DS-8201a, INFLIXIMAB, CISPLATIN, MYCOPHENOLATE MOFETIL, CAPECITABINE, KEYTRUDA 25 mg/mL concentrate for solution for infusion, FLUOROURACIL, Rilvegostomig, OXALIPLATIN, TRASTUZUMAB
AstraZeneca AB
HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.
1 trial -
CHLORAMBUCIL, FLUDARABINE PHOSPHATE, Lisaftoclax, ACALABRUTINIB, Lisaftoclax, Lisaftoclax, RITUXIMAB, CYCLOPHOSPHAMIDE MONOHYDRATE, RITUXIMAB
Pharma Mar S.A.
Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
1 trial -
CPT Dermatophagoides pteronyssinus LETI 100 HEP/ml, Formodual 100/6 microgramos/pulsación Solución para inhalación en envase a presión, Montelukast Teva 10 mg comprimidos recubiertos con película EFG, Budesonida Aldo-Unión- 200 microgramos/pulsación suspensión para inhalación en envase a presión., Salbutamol Aldo-Unión 100 microgramos/dosis suspensión para inhalación en envase a presión, AVAMYS 27.5 micrograms/spray, nasal spray suspension, Formodual Nexthaler 200 microgramos/6 microgramos por inhalación po
Pharma Mar S.A.
Allergic rhinoconjunctivitis to Dermatophagoides pteronyssinus and Dermatophagoides farinae
1 trial -
CS1003, Placebo, LENVATINIB
Pharma Mar S.A.
Unresectable advanced hepatocellular carcinoma
1 trial -
CTX001
S.A.
Beta-Thalassemia
3 trials -
CTX001
S.A.
Sickle Cell Disease
2 trials -
Calquence 100 mg hard capsules
Pharma Mar S.A.
Relapsed or Refractory Chronic Lymphocytic Leukemia
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources